STA 5326

Known as: STA-5326, STA5326 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Apilimodapilimod mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer
The Interleukin-23 (IL-23)/IL-23R signaling axis is an important inflammatory pathway, involved in the stimulation and regulation… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2011
Review
2011
New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Interleukin (IL)-23 is an important regulator of T helper-17 lymphocytes, which influence the cutaneous immune system by… (More)
Is this relevant?
Review
2010
Review
2010
[Therapeutic effect of the low molecular weight inhibitor of the NF-kappaB signaling pathway on experimental autoimmune uveoretinitis].
The nuclear factor-kappaB (NF-kappaB) proteins are a family of ubiquitously expressed transcriptional proteins in most immune and… (More)
Is this relevant?
2010
2010
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
BACKGROUND Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes… (More)
Is this relevant?
2008
2008
Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis
INTRODUCTION The purpose of this study was to determine if oral administration of the interleukin (IL) 12/IL-23 inhibitor, STA… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
OR.95. Therapeutic Effect of the IL-12/IL-23 Inhibitor STA5326 in Experimental Autoimmune Uveoretinitis
 
Is this relevant?
2008
2008
Therapeutic Effect of the IL-12/IL-23 Inhibitor STA5326 in Experimental Autoimmune Uveoretinitis
 
Is this relevant?
2006
2006
Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.
The interleukin-12 (IL-12) cytokine induces the differentiation of naive T cells to the T helper cell type 1 (Th1) phenotype and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2006
2006
STA5326 is a well-tolerated and effective treatment for active Crohn's disease
  • Nature Clinical Practice Gastroenterology…
  • 2006
An Australian team has shown that fecal levels of S100A12—a calcium-binding protein found at high concentrations in the serum of… (More)
Is this relevant?
2006
2006
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
BACKGROUND Intestinal inflammation associated with Crohn's disease is characterized by a type 1 helper T cell response and… (More)
Is this relevant?